PRLD

Dopo l'orario di chiusura: 2.17 0.10 +4.83%

Prelude Therapeutics Inc (PRLD)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Prelude Therapeutics Inc

(302) 467-1280

175 INNOVATION BOULEVARD, WILMINGTON

Prossima data di guadagno

Ultimi documenti SEC

PRLD's Discussions on Twitter

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-11-21	Downgrade	BofA Securities	Neutral → Underperform
2022-09-09	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-07-29	Iniziato	Jefferies	Buy
2022-03-15	Downgrade	BofA Securities	Buy → Neutral
2022-02-28	Downgrade	Barclays	Overweight → Equal Weight
2021-10-08	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-07-27	Aggiornamento	BofA Securities	Neutral → Buy
2021-04-26	Iniziato	H.C. Wainwright	Buy
2021-03-09	Iniziato	Barclays	Overweight
2020-11-20	Downgrade	BofA Securities	Buy → Neutral
2020-10-20	Iniziato	BofA Securities	Buy
2020-10-20	Iniziato	Goldman	Neutral
2020-10-20	Iniziato	Morgan Stanley	Equal-Weight

Mostra tutto

Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie

Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari

Prelude Therapeutics Inc (PRLD)

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie

Invesco S&P SmallCap Materials ETF (NASDAQ:PSCM) Short Interest Up 22.6% in September - Defense World

First Trust NASDAQ ABA Community Bank Index Fund (NASDAQ:QABA) Short Interest Update - Defense World

RF Acquisition Corp. (NASDAQ:RFAC) Short Interest Update - Defense World

Nordstrom, Inc. (NYSE:JWN) Shares Sold by Axa S.A. - Defense World

Employees Retirement System of Texas Makes New Investment in Nova Ltd. (NASDAQ:NVMI) - Defense World

FDA Issues Draft Guidance on Multiregional Clinical Trials in Oncology - MyChesCo

Firstsource Acquires Ascensos - MENAFN.COM

Firstsource acquires UK-based Ascensos for $56 million - The Economic Times

Angel Capital weaves passage to glory in Guineas Prelude - Horse Betting

19 Sundance Movies to Watch Before Seeing These Filmmakers’ New Fall 2024 Releases - Sundance Institute

First Taste: At Prelude, Southern-inspired flavors get the fine-dining spotlight. - 7x7

Prelude Therapeutics (NASDAQ:PRLD) Upgraded to Strong-Buy by HC Wainwright - MarketBeat

Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MyChesCo

Data clang on Street for Prelude but SMARCA2 overtures continue - BioWorld Online

Healthy Upside Potential: Prelude Therapeutics Inc (PRLD) - SETE News

Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia - MyChesCo

Prelude Therapeutics Inc (PRLD) deserves closer scrutiny - US Post News

Prelude Therapeutics (NASDAQ:PRLD) Receives “Market Outperform” Rating from JMP Securities - Defense World

A Closer Look at Prelude Therapeutics Inc (PRLD) Stock Gains - The InvestChronicle

Glioblastoma Treatment Drugs, Pipeline Insights, Emerging Therapies, and Companies 2024 - openPR

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate - Simply Wall St

Ratios Reveal: Breaking Down Prelude Therapeutics Inc (PRLD)’s Financial Health - The Dwinnex

Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment - MyChesCo

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - Yahoo Finance

Prelude Therapeutics (NASDAQ:PRLD) Receives Neutral Rating from HC Wainwright - Defense World

Prelude Therapeutics Unveils Promising Data on PRT3789 at ESMO Congress 2024 - MyChesCo

Prelude Therapeutics' (PRLD) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat

Prelude Therapeutics (NASDAQ:PRLD) Shares Up 2.3% - MarketBeat

Prelude reports safety of new cancer drug at ESMO Congress By Investing.com - Investing.com Canada

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 - Yahoo Finance

SFA Therapeutics Appoints Dr. Ananda Gubbi as Director of Biostatistics to Enhance Drug Development - MyChesCo

Glioblastoma Pipeline Drugs, Treatment Therapies, Clinical Trials, and Companies 2024 - openPR

A Look at Prelude Therapeutics Inc (PRLD) Shares in the Recent Past Indicates Growth - SETE News

Financial Metrics Check: Prelude Therapeutics Inc (PRLD)’s Ratios for Trailing Twelve Months - The Dwinnex

Prelude Therapeutics Inc (PRLD) did well last session? - US Post News

MSD discontinues two Phase III Keytruda trials - Clinical Trials Arena

Windtree Therapeutics Reports Second-Quarter Financial Results and Key Business Updates - MyChesCo

Glioblastoma Pipeline Drugs 2024 | Denovo BioPharma, Pfizer, - openPR

The Globe and Mail - The Globe and Mail

HC Wainwright Equities Analysts Lower Earnings Estimates for Prelude Therapeutics Incorporated (NASDAQ:PRLD) - MarketBeat

Vanguard Group Inc. Raises Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Vanguard Group Inc. Buys 10,143 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

HC Wainwright Weighs in on Prelude Therapeutics Incorporated’s Q1 2025 Earnings (NASDAQ:PRLD) - Defense World

Prelude Therapeutics (NASDAQ:PRLD) Rating Reiterated by HC Wainwright - Defense World

Prelude Therapeutics Incorporated Forecasted to Post Q1 2025 Earnings of ($0.49) Per Share (NASDAQ:PRLD) - MarketBeat

HC Wainwright Reaffirms Neutral Rating for Prelude Therapeutics (NASDAQ:PRLD) - MarketBeat

Pathos AI Licenses PRT811 From Prelude Therapeutics - Contract Pharma

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 46.0% in July - MarketBeat

Prelude Therapeutics (NASDAQ:PRLD) Issues Quarterly Earnings Results, Meets Estimates - MarketBeat

PRLD stock soars to 52-week high, touches $6.8 amid growth - Investing.com India

Financial Review: Prelude Therapeutics (NASDAQ:PRLD) and Intra-Cellular Therapies (NASDAQ:ITCI) - Defense World

Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a PRLD